Waters (WAT) Q2 FY26 earnings call

Waters Corporation delivered a strong Q2 FY26, driven by robust organic growth and significant acceleration in its newly acquired Biosciences and Diagnostic Solutions businesses. The company exceeded revenue and EPS guidance, benefiting from strong commercial execution, new product innovation, and improving end-market conditions, particularly in pharma and academic/government segments. Strategic initiatives, including a 180-day revitalization plan for acquired assets and cost actions, are progressing ahead of schedule, positioning the company for continued growth and margin expansion despite c